Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma

Exclusion Criteria

• •1. History of another malignancy that has not been in complete remission for at least 2 years, except for: non-melanoma skin cancer, completely resected stage I tumors with low recurrence potential, treated localized prostate cancer, biopsy-confirmed cervical carcinoma in situ, or squamous intraepithelial lesions detected by Pap smear and so on.
• •2. Active Hepatitis B: a) Positive for Hepatitis B surface antigen (HBsAg) and/or Hepatitis B core antibody (HBcAb) , with HBV-DNA below the lower limit of the reference value can be included.
• •3. Hepatitis C, HIV, or syphilis infection.
• •4. Uncontrolled systemic fungal, bacterial, viral, or other infections.
• •5. Acute or chronic graft-versus-host disease (GVHD).
• •6. Known hypersensitivity or allergy to any study drug or excipient.
• •7. Clinically significant central nervous system (CNS) disease or symptoms, such as epilepsy, seizures, paralysis, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychiatric illness.
• •8. Pregnant or breastfeeding women, and women of childbearing age who do not wish to use contraception.
• •9. Mentally ill individuals or those unable to provide informed consent.
• •10. The investigator deems the patient unsuitable for the study due to medical, psychological, familial, social, or geographical reasons or an inability to comply with the study protocol.
• •11. Previous CAR-T cell therapy or other gene-modified T-cell treatments.
• •12. Previous CD19-targeted therapy.
• •13. Previous allogeneic hematopoietic stem cell transplantation.